HP Specific Neutra™ Antibody Products

Struggling with prolonged drug development timelines or challenges in neutralizing HP-mediated pathologies? Creative Biolabs' HP specific Neutra™ antibody products leverage advanced antibody engineering to accelerate therapeutic discovery and streamline validation workflows, delivering high-affinity tools for precise HP targeting.

Introduction to HP

Haptoglobin (HP), a glycoprotein synthesized primarily in the liver, is a critical component of the acute-phase response. It binds free hemoglobin (Hb) with high specificity, forming stable HP-Hb complexes that mitigate oxidative tissue damage and facilitate their clearance via CD163 receptors on macrophages. HP exists in three major phenotypes (HP1-1, HP2-1, HP2-2) due to genetic polymorphisms, influencing its functional efficacy in disease contexts.

Fig.1 Role of HP in Hb clearance following hemolysis.¹

• Structure

HP comprises two α-chains and two β-chains linked by disulfide bonds. The α-chain determines its phenotypic variation, while the β-chain mediates Hb binding. The quaternary structure allows HP to adsorb extracellular Hb, inhibiting iron-mediated reactive oxygen species (ROS) production. Structural studies reveal conformational flexibility in its Hb-binding domain, a feature exploited by neutralizing antibodies to block complex formation.

• Related Signaling Pathways

HP modulates the CD163-HO-1 pathway by directing HP-Hb complexes to macrophages, triggering anti-inflammatory heme oxygenase-1 (HO-1) expression. Dysregulation of this pathway exacerbates oxidative stress in conditions like hemolytic anemia, atherosclerosis, and chronic kidney disease. Additionally, HP influences immune modulation through interactions with the TLR4/NF-κB axis, amplifying inflammatory cascades in metabolic disorders.

• Associated Pathologies

Elevated HP levels correlate with inflammatory states, including rheumatoid arthritis, sepsis, and diabetes mellitus. Conversely, HP deficiency exacerbates hemolysis-driven complications, such as acute kidney injury. HP's dual role as a scavenger and immune modulator underscores its therapeutic relevance in managing inflammatory and hemolytic disorders.

Applications of Anti-HP Neutralizing Antibodies

• Therapeutic Development for Hemolytic Disorders

Anti-HP antibodies prevent HP-Hb complex formation, which reduces iron excess and oxidative stress in hemolytic anemia. This approach mitigates end-organ damage, offering a novel strategy for transfusion-dependent patients.

• Diagnostic Biomarker Validation

HP levels serve as prognostic markers in cardiovascular and metabolic diseases. Neutralizing antibodies improve diagnostic assay precision by specifically collecting free HP or HP-Hb complexes, enabling reliable quantification in serum or plasma samples.

• Inflammation and Immune Modulation Research

By blocking HP-CD163 signaling, these antibodies reduce macrophage-driven inflammation in chronic diseases. Applications include studying HP's role in diabetic nephropathy and testing anti-inflammatory therapeutics in preclinical models.

• Vaccine Adjuvant Characterization

HP-neutralizing antibodies evaluate vaccine-induced immune responses by monitoring HP phenotype-specific antibody titers, aiding in the development of personalized vaccines for high-risk populations.

Our Anti-HP Neutralizing Antibodies

Creative Biolabs' HP specific Neutra™ antibody products empower researchers to overcome challenges in HP-targeted drug development and biomarker analysis. With thoroughly verified specificity and multifunctional utility, these antibodies expedite advances in inflammation, hemolysis, and metabolic illness research.

Our anti-HP neutralizing antibodies are engineered to disrupt HP-Hb binding or interfere with HP-CD163 interactions. These antibodies exhibit:

- High specificity: Validated against all HP phenotypes via epitope mapping.

- Functional blocking: Neutralize HP's pro-oxidant effects in vitro and in vivo.

- Cross-application compatibility: Optimized for ELISA, Western blotting, and immunohistochemistry.

Preclinical studies demonstrate their utility in reducing Hb-induced renal damage and attenuating inflammation in murine models of atherosclerosis.

Contact our team today to explore custom solutions for your project.

REFERENCE

1. Edwards, Olivia, et al. "Influence of haptoglobin polymorphism on stroke in sickle cell disease patients." Genes 13.1 (2022): 144. Distributed under Open Access license CC BY 3.0, without modification. https://doi.org/10.3390/genes13010144